Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.12 | -0.05 | 0.09 |
| FCF Yield | -1.63% | -9.03% | -18.83% | -11.00% |
| EV / EBITDA | -53.35 | -19.27 | -10.56 | -8.65 |
| Quality | ||||
| ROIC | -10.34% | -33.22% | -33.17% | -20.27% |
| Gross Margin | 87.50% | 87.25% | 86.94% | 87.14% |
| Cash Conversion Ratio | 0.47 | 0.83 | 0.90 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 5,279,804.92% | 4,849,246.28% | 4,341,889.93% | 3,808,651.76% |
| Free Cash Flow Growth | 77.50% | 26.16% | -33.86% | 0.04% |
| Safety | ||||
| Net Debt / EBITDA | 9.66 | -7.31 | -4.63 | 1.71 |
| Interest Coverage | -0.95 | -3.42 | -4.36 | -3.20 |
| Efficiency | ||||
| Inventory Turnover | 1.71 | 1.47 | 1.18 | 1.19 |
| Cash Conversion Cycle | 138.30 | 106.47 | -89.48 | -54.48 |